Morgan Stanley Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Key Points

• Morgan Stanley raised Biogen’s price target from $231 to $238 while maintaining an “equal weight” rating, implying roughly 5% downside from the prior close.
• Analyst sentiment is generally positive: Biogen has a consensus “Moderate Buy” rating and an average price target of $250.17, although some firms remain neutral.
• Biogen recently exceeded quarterly earnings and revenue expectations, reporting $2.62 in adjusted EPS and $2.80 billion in revenue, while institutional investors own approximately 87.93% of the stock.

Biogen (NASDAQ:BIIB - Get Free Report) had its price target hoisted by Morgan Stanley from $231.00 to $238.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an "equal weight" rating on the biotechnology company's stock. Morgan Stanley's price objective points to a potential downside of 5.15% from the stock's previous close.

A number of other research analysts have also weighed in on BIIB. Wall Street Zen lowered shares of Biogen from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Citigroup restated a "neutral" rating on shares of Biogen in a report on Wednesday. Oppenheimer reaffirmed an "outperform" rating and issued a $300.00 price target on shares of Biogen in a research report on Wednesday, July 29th. Jefferies Financial Group reiterated a "buy" rating on shares of Biogen in a research note on Monday, July 13th. Finally, Guggenheim boosted their price objective on Biogen from $260.00 to $280.00 and gave the stock a "buy" rating in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $250.17.

Biogen Price Performance

NASDAQ:BIIB traded up $6.88 on Thursday, hitting $250.94. The company had a trading volume of 411,039 shares, compared to its average volume of 1,212,450. The stock has a market capitalization of $37.08 billion, a price-to-earnings ratio of 44.40, a PEG ratio of 2.99 and a beta of 0.09. Biogen has a 52 week low of $138.00 and a 52 week high of $258.78. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The firm has a 50 day moving average of $225.73 and a two-hundred day moving average of $200.39.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. The company had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.63 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.81 earnings per share. On average, research analysts anticipate that Biogen will post 12.29 earnings per share for the current year.

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Biogen during the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA acquired a new stake in Biogen in the 2nd quarter valued at $3,274,304,000. Legal & General Group Plc purchased a new position in Biogen in the 2nd quarter worth approximately $322,640,000. Bank of America Corp DE purchased a new stake in shares of Biogen in the 2nd quarter valued at approximately $241,172,000. Finally, Deutsche Bank AG acquired a new stake in shares of Biogen during the 2nd quarter worth about $193,165,000. 87.93% of the stock is owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Quarterly results exceeded expectations. Biogen reported adjusted earnings of $2.62 per share versus the roughly $1.99–$2.06 consensus and revenue of $2.80 billion versus estimates near $2.63 billion. Revenue rose 10.6% year over year, supporting the view that newer products are offsetting pressure on older multiple-sclerosis therapies. Biogen third-quarter earnings report
• Positive Sentiment: Growth portfolio momentum was a key catalyst. Growth-portfolio revenue increased 49% to approximately $1.26 billion, helped by rare-disease products and the first full quarter of revenue from assets acquired through Apellis. Biogen raised the lower end of its full-year 2026 adjusted EPS outlook to $12.20, while management described the company as having returned to growth. Biogen Q3 earnings and outlook
• Positive Sentiment: Analysts became more bullish after the earnings beat. Needham and Baird raised their targets to $290, UBS lifted its target to $300 while maintaining a buy rating, RBC raised its target to $272, and TD Cowen and Truist increased targets to $260. Argus upgraded Biogen from hold to buy with a $280 target. Analyst target increases
• Positive Sentiment: Upcoming Alzheimer’s data could provide another catalyst. Biogen plans to present long-term and real-world data for lecanemab, including five-year Clarity AD extension results, as well as additional Phase 2 CELIA data for diranersen at the November CTAD conference. Biogen CTAD 2026 data announcement
• Neutral Sentiment: Biogen posted a GAAP loss of $20.6 million, or $0.14 per share, primarily because of acquisition-related research, development and milestone expenses. The stronger adjusted results and revenue growth outweighed the accounting loss for investors, but integration costs remain a consideration. Biogen Q3 revenue and GAAP loss
• Negative Sentiment: Barclays raised its price target to $230 but retained an equal-weight rating, implying downside relative to the current valuation. Separately, unusually high put-option activity signals that some traders remain cautious after the stock’s strong run.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.